What is 4basebio?
4basebio is at the forefront of designing and manufacturing GMP-grade synthetic DNA and non-viral nanoparticles, crucial components for efficient gene delivery. Their proprietary, customizable technologies offer distinct advantages over conventional plasmid DNA and non-targeted lipid nanoparticles. The company's solutions are engineered for critical applications including gene therapy, DNA vaccines, gene editing, and targeted delivery systems, positioning them as a key partner for pharmaceutical and biotechnology firms seeking cutting-edge gene synthesis and delivery capabilities.
How much funding has 4basebio raised?
4basebio has raised a total of $1.6M across 1 funding round:
Other Financing Round
$1.6M
Other Financing Round (2025): $1.6M with participation from Government of Canada
Key Investors in 4basebio
Government of Canada
The Government of Canada is the federal governing body of Canada, responsible for national policy and administration across various sectors. Its involvement in funding suggests a strategic interest in advancing Canadian biotechnology and life sciences innovation.
What's next for 4basebio?
The recent major enterprise-level funding indicates a strategic pivot or significant scaling phase for 4basebio. This capital infusion is likely to accelerate the development and commercialization of their advanced gene delivery platforms, potentially expanding their market reach into new therapeutic areas or enhancing their manufacturing capacity to meet growing industry demand. The focus on gene therapy and DNA vaccines suggests a strong trajectory towards clinical applications and market penetration.
See full 4basebio company page
